alexa Assessment of Cholesterol Absorption and Synthesis in J
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Assessment of Cholesterol Absorption and Synthesis in Japanese Patients with Type-2 Diabetes and Lipid-Lowering Effect of Ezetimibe

Tomoko Nakagami*, Yayoi Yamamoto, Sayaka Fukushima, Junko Oya, Yasuhiko Iwamoto and Yasuko Uchigata

Department of Internal Medicine, Diabetes Center, Tokyo Women’s Medical University School of Medicine, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan

Corresponding Author:
Tomoko Nakagami
Department of Internal Medicine
Diabetes Center, Tokyo Women’s Medical University School of Medicine
8-1, Shinjuku-ku, Tokyo 162-8666, Japan
Tel: 81-3-3353-8111
Fax: 81-3-3358-1941
E-mail: [email protected]

Received Date: May 25, 2011; Accepted Date: September 10, 2011; Published Date: September 14, 2011

Citation: Nakagami T, Yamamoto Y, Fukushima S, Oya J, Iwamoto Y, et al. (2011) Assessment of Cholesterol Absorption and Synthesis in Japanese Patients with Type-2 Diabetes and Lipid-Lowering Effect of Ezetimibe. J Diabetes Metab 2:139. doi:10.4172/2155-6156.1000139

Copyright: © 2011 Nakagami T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Aims: Cholesterol absorption is reported as an independent risk factor for cardiovascular disease. However, factors related to cholesterol absorption have not been fully examined in patients with type-2 diabetes (T2DM). The aim of this study was to assess cholesterol absorption/synthesis markers and the effect of an inhibitor of cholesterol absorption, ezetimibe, in patients with T2DM with hyper-low-density lipoprotein cholesterolemia. Methods: We included 59 patients treated with statins (S group) and 121 patients who were not receiving any Lipid lowering treatments (N group). Levels of cholesterol absorption and synthesis markers were compared between the 2 groups and between subjects in the N group with and without microvascular complications. The lipid-lowering effect of ezetimibe treatment (10 mg/day for 12 weeks) was examined in 70 patients with high levels of low-density lipoproteincholesterol (LDL-C). These patients were divided into the monotherapy (M) group (n=57; ezetimibe treatment only) and the combination therapy (C) group (n=13; ezetimibe and statin treatment). Results: The levels of cholesterol absorption and synthesis markers were higher and lower, respectively, in patients in the S group than in the N group (both p<0.05). In the N group, the cholesterol-absorption marker levels were higher in patients with microvascular complications than in those without (p<0.05). Ezetimibe decreased total cholesterol and LDL-C levels by 13% and 21% and 11% and 16% in patients in the M group and C group, respectively (all p<0.05). In patients of the M group, ezetimibe decreased the levels of remnant-like particle-cholesterol, high-sensitivity c-reactive protein, and triglycerides (TG; only in cases with TG=150 mg/dL) by 16%, 5%, and 21%, respectively, and increased high-density lipoprotein-cholesterol by 6.8% (all p 0.05). Results: The levels of cholesterol absorption and synthesis markers were higher and lower, respectively, in patients in the S group than in the N group (both p < 0.05). In the N group, the cholesterol-absorption marker levels were higher in patients with microvascular complications than in those without (p < 0.05). Ezetimibe decreased total cholesterol and LDL-C levels by 13% and 21% and 11% and 16% in patients in the M group and C group, respectively (all p < 0.05). In patients of the M group, ezetimibe decreased the levels of remnant-like particle-cholesterol, high-sensitivity c-reactive protein, and triglycerides (TG; only in cases with TG = 150 mg/dL) by 16%, 5%, and 21%, respectively, and increased high-density lipoprotein-cholesterol by 6.8% (all p 0.05). Conclusions: Ezetimibe may be a useful therapeutic option to prevent micro- and macrovascular complications for dyslipidemia in patients with T2DM.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords